Cellegy Savvy HIV prevention trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Cellegy's Phase III HIV prevention trial of the microbicide Savvy (C31G vaginal gel) has reached 50% enrollment, the firm announces March 3. Cellegy estimates 1,500 women have enrolled in the Ghana-based trial since initiation in March 2004. A second trial is underway in Nigeria; both are slated to complete in late 2006. A third study is being conducted in the U.S. and has enrolled 200 patients. Cellegy claims Savvy is the most advanced microbicide in development for HIV prevention. "Savvy has also shown activity that suggests protection against...herpes simplex virus, chlamydia, trichomonas, gonorrhea and syphilis," the firm notes. Cellegy's Biosyn subsidiary is conducting the Savvy trials...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.